

Diverse neurological effects linked to anti-PD-1 therapy

September 11 2017



(HealthDay)—Neurological complications associated with anti-

programmed death 1 (PD-1) antibody treatment have a diverse phenotype, according to a study published online Sept. 5 in *JAMA Neurology*.

Justin C. Kao, M.B.Ch.B., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a [retrospective cohort study](#) involving patients with development of neurological symptoms within 12 months of receiving anti-PD-1 therapy.

The researchers found that 2.9 percent of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of [neurological complications](#). Seven of these patients received pembrolizumab and three nivolumab. Neurological complications occurred after a median of 5.5 anti-PD-1 inhibitor cycles. Myopathy, varied neuropathies, cerebellar ataxia, autoimmune retinopathy, bilateral internuclear ophthalmoplegia, and headache were reported complications. Reported [peripheral neuropathies](#) were axonal and demyelinating polyradiculoneuropathies, length-dependent neuropathies, and asymmetric vasculitic neuropathy.

"Neurological adverse events associated with anti-PD-1 therapy have a diverse phenotype, with more frequent neuromuscular complications," the authors write. "Prompt recognition and discontinuation of anti-PD-1 [therapy](#) is recommended. In some cases, immune rescue treatment may be required."

One author disclosed financial ties to the pharmaceutical industry.

More information: [Abstract/Full Text](#)
[Editorial](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Diverse neurological effects linked to anti-PD-1 therapy (2017, September 11)
retrieved 12 May 2024 from <https://medicalxpress.com/news/2017-09-diverse-neurological-effects-linked-anti-pd-.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.